microbiological pipette in the genetic laboratory
Our Work

Latham & Watkins Advises on Structure Therapeutics’ Upsized IPO

February 3, 2023
San Diego capital markets team represented the underwriters in the offering by the clinical-stage global biopharmaceutical company.

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, has announced the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of US$15.00 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be US$161.1 million before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,611,000 ADSs at the initial public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Structure Therapeutics. The shares began trading on the Nasdaq Global Market on February 3, 2023 under the ticker symbol “GPCR.” The offering is expected to close on February 7, 2023, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a San Diego capital markets team led by partners Matt Bush and Cheston Larson, with associates Julian Brody and Rachel Staub.